A bipartisan Senate Finance Health Subcommittee hearing focused on linking antimicrobial resistance strategy with efforts to preserve U.S. biotech leadership. Lawmakers discussed the scale of AMR harm, the difficulty of sustaining returns for novel antimicrobials, and policy mechanisms that could support R&D investment. Witnesses included Kevin Outterson, whose CARB-X program leads a public-private partnership to fund new antimicrobials, and infectious disease expert Vera Luther of Dartmouth Hitchcock Medical Center, who cited mortality and healthcare cost burdens from major resistant threats. The hearing also reiterated support for the Senate version of the PASTEUR Act and referenced recommendations from the National Security Commission on Emerging Biotechnology, framing both as components of a coordinated domestic innovation and security agenda.